Tim Wilsdon recently presented at an education forum at ISPOR Latin America, talking about the challenges that gene therapy poses for value assessment and considerations for the future.
For more information about the conference, click here.
MFN is rewriting the launch planning playbook: Commercial and market access strategies must integrate to succeed
MFN-related uncertainty is reshaping pharmaceutical launch planning by making pricing, sequencing, and forecasting decisions more interconnected and...